

Technology Appraisal Committee B Interests Register

Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer ID3920

Publication Date: 07 February 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Peter Wheatley Price	TAC B Committee Member	Indirect - Financial Interests	Olaparib. Takeda manufacture Leuprorelin (Prostap) a LHRH agonist used in hormone sensitive stages. Previous appraisals at this stage have been declare and participate.	12/09/2023	N/A	It was agreed that Peter's declaration would not prevent him participating in the appraisal committee.
Rhiannon Owen	TAC B Committee Member	Direct - Financial Interests	Paid consultant for AstraZeneca participating in an advisory board for an economic model in metastatic breast cancer which took place on 31st March 2023.	19/09/2023	N/A	It was agreed that Rhiannon's declaration would not prevent her participating in the appraisal committee.
Professor Noel Clarke	Clinical Expert	Direct - Financial interests	Honoraria for national / international lectures relating to prostate and other GU cancers. Honoraria have been received from pharmaceutical companies (Astrazeneca, Bayer, Pfizer, Novartis, Astellas and	04/10/2023	N/A	It was agreed that Noel's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p>Janssen pharmaceuticals) comprising payment for work done in researching the available scientific data from current and historical trials, preparing slides and themes for presentation and physically travelling to and delivering lectures at National/international symposia addressing the topic of genito-urinary cancer, particularly prostate cancer</p> <p>Honoraria for advisory boards for all major pharmaceutical companies involved in contemporary systemic treatments relating to prostate cancer and prostate cancer trial development. These include Astrazeneca, Bayer, Pfizer, Novartis, Astellas and Janssen pharmaceuticals. This work has been as an independent key opinion leader scrutinising data from current</p>			

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			trials and advising on planning future areas requiring acquisition of trial-based and registration based data on GU cancer			
Professor Noel Clarke	Clinical Expert	Direct - Financial interests	Noel is the joint principal global investigator for the AstraZeneca ProPel Trial of PARP Inhibition in metastatic castrate resistant prostate cancer.	04/102023	N/A	It was agreed that Noel's declaration would not prevent him from providing expert advice to the committee.
Professor Suneil Jain	Clinical Expert	Direct financial interests	Consultancy with Boston Scientific (peri-rectal spacer product for prostate radiotherapy. Advisory Board – Pfizer. PARP inhibitor use in prostate cancer. Advisory Board – Accord healthcare. Hormonal therapy (relugolix) prostate cancer	04/102023	N/A	It was agreed that Suneil's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p>Travel and speaker fees – Janssen, Astellas and Bayer</p> <p>Advisory Board – Astra Zeneca – May 2023</p>			
Professor Suneil Jain	Clinical Expert	Direct – non financial	<p>Local-PI of the Amplitude study (Janssen) – evaluating the use of PARP inhibitors in metastatic hormone sensitive prostate cancer.</p> <p>Local-PI and TMG member – the ACE study – a Phase I/II study of a CXCR 1/2 inhibitor in metastatic castrate resistant prostate cancer. Drug was owned and provided by Astra Zeneca.</p> <p>Suneil was local-PI and a member of the trial management group for the TOPARP clinical trial – olaparib in metastatic prostate cancer</p>	04/102023	N/A	

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments